Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- P/B of 2.92 — trading above book value
- Piotroski F-Score 4/9 — moderate financial health
- Loss-making — negative ROE of -17.3%
GH Research PLC (GHRS) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $816 million . Key value metrics: P/B ratio 2.92, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
GH Research PLC — Fundamental Analysis Summary
On financial health, GHRS shows a moderate Piotroski F-Score of 4/9, and negative return on equity of -17.3% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.00.
StockPik's composite Value Score for GHRS is 55/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
GHRS shows earnings declining at 24%.